For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
After finishing at $29.72 in the prior trading day, Legend Biotech Corp ADR (NASDAQ: LEGN) closed at $29.42, down -1.01%. In other words, the price has decreased by -$1.01 from its previous closing price. On the day, 1.54 million shares were traded. LEGN stock price reached its highest trading level at $29.785 during the session, while it also had its lowest trading level at $29.26.
Ratios:
Our goal is to gain a better understanding of LEGN by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.80 and its Current Ratio is at 2.86. In the meantime, Its Debt-to-Equity ratio is 0.41 whereas as Long-Term Debt/Eq ratio is at 0.26.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of . The stock’s future direction. In the most recent recommendation for this company, Cantor Fitzgerald on October 07, 2025, initiated with a Overweight rating and assigned the stock a target price of $40.
On October 08, 2024, Redburn Atlantic started tracking the stock assigning a Buy rating and target price of $86.
On June 17, 2024, Truist started tracking the stock assigning a Buy rating and target price of $88.Truist initiated its Buy rating on June 17, 2024, with a $88 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 17 ’25 when GenScript Corporation bought 203,586 shares for $30.29 per share.
Casey Patrick John bought 1,000 shares of LEGN for $33,285 on Sep 26 ’25. On Sep 24 ’25, another insider, Huang Ying, who serves as the Officer of the company, bought 1,370 shares for $33.00 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, LEGN now has a Market Capitalization of 5433567232 and an Enterprise Value of 10284780544. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.97 while its Price-to-Book (P/B) ratio in mrq is 5.37. Its current Enterprise Value per Revenue stands at 11.314 whereas that against EBITDA is -56.747.
Stock Price History:
The Beta on a monthly basis for LEGN is 0.10, which has changed by -0.2595914 over the last 52 weeks, in comparison to a change of 0.1276468 over the same period for the S&P500. Over the past 52 weeks, LEGN has reached a high of $45.30, while it has fallen to a 52-week low of $27.34. The 50-Day Moving Average of the stock is -9.33%, while the 200-Day Moving Average is calculated to be -14.84%.
Shares Statistics:
The stock has traded on average 1.26M shares per day over the past 3-months and 1456970 shares per day over the last 10 days, according to various share statistics. A total of 184.69M shares are outstanding, with a floating share count of 180.89M. Insiders hold about 2.06% of the company’s shares, while institutions hold 44.42% stake in the company. Shares short for LEGN as of 1761868800 were 10772670 with a Short Ratio of 8.56, compared to 1759190400 on 9351983. Therefore, it implies a Short% of Shares Outstanding of 10772670 and a Short% of Float of 11.16.
Earnings Estimates
. The current market rating for Legend Biotech Corp ADR (LEGN) reflects the collective analysis of 6.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is $0.0, with high estimates of $0.0 and low estimates of $0.0.
Analysts are recommending an EPS of between -$0.82 and -$0.91 for the fiscal current year, implying an average EPS of -$0.87. EPS for the following year is $0.56, with 8.0 analysts recommending between $0.99 and $0.08.
Revenue Estimates
10 analysts predict $319.8M in revenue for . The current quarter. It ranges from a high estimate of $368.26M to a low estimate of $302.15M. As of . The current estimate, Legend Biotech Corp ADR’s year-ago sales were $186.52MFor the next quarter, 10 analysts are estimating revenue of $324.52M. There is a high estimate of $378.75M for the next quarter, whereas the lowest estimate is $300M.
A total of 13 analysts have provided revenue estimates for LEGN’s current fiscal year. The highest revenue estimate was $1.09B, while the lowest revenue estimate was $1.01B, resulting in an average revenue estimate of $1.04B. In the same quarter a year ago, actual revenue was $627.24MBased on 14 analysts’ estimates, the company’s revenue will be $1.56B in the next fiscal year. The high estimate is $1.91B and the low estimate is $1.37B.
